Perrigo Company announced that the FDA has granted final approval to Tris Pharma for Dextromethorphan Polistirex extended-release oral suspension, the store-brand equivalent to Reckitt Benckiser‘s Delsym suspension.
Delsym suspension, an over-the-counter (OTC) antitussive, is indicated for the treatment of nonproductive cough due to minor throat and bronchial irritation. This centrally-active antitussive acts in the CNS to increase the threshold for cough. While it does not provide analgesia, it does produce less GI adverse effects and does not cause drug dependence.
Perrigo expects to begin shipment of this product in early 2013.
For more information call (800) 719-9260 or visit www.perrigo.com.